E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Not possible to specify |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049909 |
E.1.2 | Term | Venous thromboembolism prophylaxis |
E.1.2 | System Organ Class | 100000004865 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the efficacy on the risk of symptomatic VTE at one month of low molecular weight heparin enoxaparin 40 mg once daily subcutaneously for 10 ± 4 days as compared with placebo in patients aged 75 years or more who have been hospitalized for an acute medical illness. |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate whether the use of prophylactic dose of low molecular weight heparin reduces the risk of symptomatic VTE at 3 months in hospitalized elderly medical patients
• To assess the risk of bleeding associated with the use of prophylactic low molecular weight heparin at 1month and at 3 months
• To assess the net clinical benefit (symptomatic VTE and major bleeding events) associated with the use of low molecular weight heparin at 1 month and at 3 months
• To assess the impact of low molecular weight heparin on atherothrombotic cardiovascular events at 1 month and 3 months
• To assess the impact of low molecular weight heparin on mortality from any cause at 1 month and at 3 months
• To assess the risk of cardiovascular death at 1 month and at 3 months
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patient aged 75 years or older
• Admitted to hospital for an acute medical illness
• Anticipated duration of hospitalization of at least 4 days
• Life expectancy of at least 3 months
|
|
E.4 | Principal exclusion criteria |
• Admission for one of the following reasons:
o Planned medical procedure.
o Routine health assessment requiring admission for baseline/trending of health status (e.g., routine colonoscopy).
o Admission encountered for another life circumstance that causes no bearing on health status and requires no medical intervention (e.g., lack of housing, economic inadequacy, care-giver respite, family circumstances, administrative).
• Hypersensitivity to heparin
• History of Heparin Induced Thrombocytopenia
• Active bleeding
• Bacterial endocarditis
• Platelet count of less than 100,000 per cubic millimeter
• Patients who require anticoagulant therapy for any indication, and those who received any type of anticoagulant therapy for > 48 hours
• Active peptic ulcer
• Concomitant use of aspirin (> 160 mg/day), clopidogrel (> 75 mg/day), or of combined antiplatelet therapy
• Previous admission to hospital within the last month
• Creatinine clearance < 15 ml/min
• Unable or unwilling to consent
• Ischemic stroke + hemorrhagic transformation
• Patient requiring admission to Intensive Care Unit
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome is the occurrence of any of the following events through the day 30 visit : symptomatic confirmed deep venous thrombosis (DVT), symptomatic confirmed pulmonary embolism (PE), or fatal PE |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary outcomes is the occurrence of any of the following events
• Symptomatic confirmed VTE (DVT or PE) or fatal PE through the day 90 visit
• Major bleeding as defined by the criteria of the International Society of Thrombosis and Haemostasis through the day 30 and the day 90 visit
• Clinically relevant non major bleeding and any bleeding through the day 30 and the day 90 visit
• Atherothrombotic cardiovascular events through the day 30 and the day 90 visit
• Cardiovascular death through the day 30 and the day 90 visit
• Death from any cause through the day 30 and the day 90 visit
All events are adjudicated by the CEC
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
day 30 and the day 90 visit
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 30 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 50 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Canada |
France |
Germany |
Italy |
Spain |
Switzerland |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
the last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 3 |